Veru Inc | DEFA14A: Others
Veru Inc | DEFR14A: Definitive proxy statement in connection with contested solicitations
Veru Inc | 8-K: Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
Veru Inc | 8-K: Forbearance Agreement
Veru Inc | 8-K: Veru Inc Regains Compliance with Nasdaq's Listing Requirements
Veru Inc | DEFA14A: Others
Veru Inc | DEFA14A: Others
Veru Inc | 8-K: Current report
Veru Inc | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
Veru Inc | 8-K: Current report
Veru Inc | 8-K: Veru Inc Announces First Quarter FY2024 Financial Highlights
Veru Inc | 8-K: Current report
Veru Inc | DEFA14A: Others
Veru Inc | DEF 14A: Definitive information statements
Veru Inc | 8-K: Veru Inc Entered into an Underwriting Agreement and Announced Pricing of Public Offering of Common Stock
Veru Inc | 8-K: Amendment of a Common Stock Purchase Agreement and Update of the Presentation of 「Discussion Planned Development of Enobosarm Initially as a Treatment」
Veru Inc | 8-K: Current report
Veru Inc | 8-K: Amendment to Asset Purchase Agreement
Veru Inc | 8-K: Veru Inc Announced Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy
Veru Inc | 8-K: Veru Inc Reports Fiscal 2023 Third Quarter Financial Results
No Data